Featured Research

from universities, journals, and other organizations

Improving efficacy of antipsychotics in the era of personalized pharmacotherapy

Date:
December 9, 2013
Source:
Université de Montréal
Summary:
The efficacy of most antipsychotics depends on their pharmacokinetics, or their ability to get into the bloodstream after being absorbed. According to data recently collected, five of the most recent second-generation antipsychotics were among the drugs with the lowest efficacy, despite having similar pharmacological properties compared to first-generation or to other second-generation antipsychotics.

The clinical context of the administration and dosage of antipsychotics may influence their efficacy, reported Philippe Vincent and Édouard Kouassi, from the Institut universitaire en santé mentale de Montréal and Université de Montréal. The efficacy of most antipsychotics depends on their pharmacokinetics, or their ability to get into the bloodstream after being absorbed.

Related Articles


Vincent and Kouassi are responding in The Lancet to Stefan Leucht, who conducted a meta-analysis of over 200 articles on the efficacy and side effects of 15 antipsychotics. According to the data Leucht collected, five of the most recent second-generation antipsychotics (ziprasidone, aripiprazole, asenapine, iloperidone and lurasidone) were among the drugs with the lowest efficacy, despite having similar pharmacological properties compared to first-generation or to other second-generation antipsychotics. Leucht published his finding in The Lancet in September 2013; his article did not give any explanations for this surprising result.

Some antipsychotics require strict adherence on the part of patients. According to Vincent and Kouassi, specific conditions are required for some medications to be effectively absorbed. "For example, ziprasidone needs to be taken twice a day with a meal of 500 calories, whereas asenapine must absolutely melt under the tongue, and the patient must abstain from swallowing it, drinking, eating or smoking for 10 minutes afterward," Vincent said "This is a major challenge since more than one half of people with psychotic disorders do not take their medication as prescribed.

Vincent and Kouassi also state that the titration of these antipsychotics is a challenge in clinical practice, as it is difficult to obtain the optimal therapeutic dosage on the first try. Doctors therefore have to use an empirical approach. "The major side effects show up well before the optimum therapeutic dose is determined, which can discourage patients from continuing their treatment," Kouassi said. "Doctors have to keep trying, as the pharmacokinetics of antipsychotic compounds differ for each patient. By adjusting the dose of a medication based on the degree of blood absorption, distribution, metabolism and elimination in a patient, doctors can personalize treatment, which becomes that much more effective. We maintain that all antipsychotics, with the exception of clozapine, can achieve the same efficacy if they reach comparable blood levels."

If the studies reported by Leucht had compared medications in terms of their blood concentrations, we would have more accurate conclusions about the efficacy of the medication. "This confirms that the future of psychiatric medicine will involve personalizing patient care," Vincent said.


Story Source:

The above story is based on materials provided by Université de Montréal. Note: Materials may be edited for content and length.


Journal Reference:

  1. Vincent P, Kouassi E. Efficacy of antipsychotic drugs for schizophrenia. The Lancet, December 2013.

Cite This Page:

Université de Montréal. "Improving efficacy of antipsychotics in the era of personalized pharmacotherapy." ScienceDaily. ScienceDaily, 9 December 2013. <www.sciencedaily.com/releases/2013/12/131209085553.htm>.
Université de Montréal. (2013, December 9). Improving efficacy of antipsychotics in the era of personalized pharmacotherapy. ScienceDaily. Retrieved November 27, 2014 from www.sciencedaily.com/releases/2013/12/131209085553.htm
Université de Montréal. "Improving efficacy of antipsychotics in the era of personalized pharmacotherapy." ScienceDaily. www.sciencedaily.com/releases/2013/12/131209085553.htm (accessed November 27, 2014).

Share This


More From ScienceDaily



More Mind & Brain News

Thursday, November 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Are Female Bosses More Likely To Be Depressed?

Are Female Bosses More Likely To Be Depressed?

Newsy (Nov. 24, 2014) — A new study links greater authority with increased depressive symptoms among women in the workplace. Video provided by Newsy
Powered by NewsLook.com
Winter Can Cause Depression — Here's How To Combat It

Winter Can Cause Depression — Here's How To Combat It

Newsy (Nov. 23, 2014) — Millions of American suffer from seasonal depression every year. It can lead to adverse health effects, but there are ways to ease symptoms. Video provided by Newsy
Powered by NewsLook.com
Could Your Genes Be The Reason You're Single?

Could Your Genes Be The Reason You're Single?

Newsy (Nov. 21, 2014) — Researchers in Beijing discovered a gene called 5-HTA1, and carriers are reportedly 20 percent more likely to be single. Video provided by Newsy
Powered by NewsLook.com
Milestone Birthdays Can Bring Existential Crisis, Study Says

Milestone Birthdays Can Bring Existential Crisis, Study Says

Newsy (Nov. 21, 2014) — Researchers find that as people approach new decades in their lives they make bigger life decisions. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins